Independent association between occupational exposure and decline of forced vital capacity in systemic sclerosis (SSc): a multicenter recruitment retrospective cohort study

PHARMA NEWS

Interstitial Lung Disease

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD¹

doi: 10.1056/NEJMoa1903076

COMMENTED

Further Publications

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF

doi: 10.1016/S2213-2600(21)00165-X

SPECIAL REPORT

Interstitial Lung Disease

OFEV^® extended indication offers new hope for patients with SSc-ILD

CoughInterstitial Lung Disease

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases

Respirology.

Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ

doi: 10.1111/resp.13084.

RECOMMENDED

Interstitial Lung Disease

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

N Engl J Med.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.

doi: 10.1056/NEJMoa1903076.

RECOMMENDED

Pulmonary Fibrosis

Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Chest.

Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS

doi: 10.1016/j.chest.2020.02.009.

RECOMMENDED

Interstitial Lung Disease

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Ann Rheum Dis.

Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators

doi: 10.1136/annrheumdis-2020-217331.

RECOMMENDED

Further Publications

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators.

doi: 10.1016/S2213-2600(20)30330-1

RECOMMENDED

COPDCoughRespiratory Tract InfectionBronchi

Airborne occupational exposures and the risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Thorax

Faruque MO, Boezen HM, Kromhout H, Vermeulen R, Bültmann U, Vonk JM

doi: 10.1136/thoraxjnl-2020-216721

Related content

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

OFEV® extended indication offers new hope for patients with SSc-ILD

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

Airborne occupational exposures and the risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD¹

OFEV^® extended indication offers new hope for patients with SSc-ILD